Welcome to our dedicated page for Zimmer Biomet news (Ticker: ZBH), a resource for investors and traders seeking the latest updates and insights on Zimmer Biomet stock.
Zimmer Biomet Holdings, Inc. reports developments across its global medical technology business, including orthopedic reconstructive implants, surgical products, and integrated digital and robotic technologies that use data, analytics and artificial intelligence. Company updates commonly cover quarterly results and guidance, dividend actions, health care conference appearances, executive leadership changes, and clinical or operational data presented at orthopedic meetings.
Product-focused announcements describe musculoskeletal care technologies such as Oxford Cementless Partial Knee, Persona OsseoTi Keel Tibia, and HAMMR Automated Hip Impaction System, alongside broader portfolio themes in knees, hips, smart implants, robotics, AI and medical education.
Zimmer Biomet (NYSE: ZBH) appointed Chintan Desai as president of its Asia Pacific region, effective immediately. Desai joins from Alcon, where he held senior international and Asia Pacific leadership roles, following a 22-year career at GE Healthcare in multiple regional positions.
His background spans sales, marketing, services, supply chain, finance and project management across medical devices and related sectors. Desai succeeds Sang Yi, group president of Asia Pacific, who will leave the company on August 28, 2026, after a transition period.
Zimmer Biomet (NYSE: ZBH) will host a webcast and conference call to discuss its second quarter 2026 financial results on Wednesday, August 5, 2026 at 8:30 a.m. ET. A news release with detailed results will be issued at 6:30 a.m. ET the same day. The live audio webcast and replay will be accessible via the company’s Investor Relations website, with U.S./Canada dial-in at (800) 330-6710 and international dial-in at +1 (213) 279-1505, both using conference ID 7090861.
Zimmer Biomet (NYSE:ZBH) announced that its management team will participate in the Goldman Sachs 47th Annual Global Healthcare Conference on Monday, June 8. A fireside chat is scheduled for 10:40 a.m. ET, with a live audio webcast and replay available on the company’s investor relations website.
Zimmer Biomet (NYSE: ZBH) announced that its Board approved a quarterly cash dividend for the second quarter of 2026. The dividend is $0.24 per share, payable on or about July 31, 2026 to stockholders of record at the close of business on June 25, 2026.
Zimmer Biomet (NYSE: ZBH) announced it now expects to repurchase up to $1 billion of common stock in fiscal 2026, a $250 million increase from its prior assumption.
All buybacks will occur under the existing $1.5 billion authorization approved in February 2026.
Zimmer Biomet (NYSE: ZBH) announced management will participate in the Bank of America Securities Health Care Conference on Wednesday, May 13, 2026, with a fireside chat at 8:40 a.m. PT (11:40 a.m. ET). A live audio webcast will be available on the company Investor Relations website and for replay after the session.
Zimmer Biomet (NYSE: ZBH) reported Q1 2026 net sales of $2.087 billion, up 9.3% reported, 6.8% constant currency and 2.9% organic constant currency. GAAP net earnings were $238.1 million and adjusted net earnings $409.4 million. Diluted EPS was $1.22 and adjusted diluted EPS $2.09. The company generated $359.4 million operating cash flow and $245.9 million free cash flow, repurchased $250 million of shares, and raised 2026 adjusted EPS and FCF expectations.
Zimmer Biomet (NYSE: ZBH) announced that Suketu Upadhyay, Chief Financial Officer and Executive Vice President, Finance, Operations and Supply Chain, will depart effective April 28, 2026, to pursue a new professional opportunity. The company named Paul Stellato, Controller and Chief Accounting Officer, as interim CFO while it conducts an internal and external search for a permanent successor.
Stellato joined Zimmer Biomet in May 2022, has more than 20 years of finance and investor-relations experience, and previously held senior finance roles at Xylem and ITT; he is a CPA with degrees from Villanova and NYU Stern.
Zimmer Biomet (NYSE: ZBH) will webcast its first quarter 2026 earnings conference call on Tuesday, April 28, 2026 at 8:30 a.m. ET. A quarterly results news release will be posted that day at 6:30 a.m. ET. The live audio webcast and replay will be available via the company's Investor Relations website, and U.S./Canada dial-in and international telephone numbers with conference ID are provided for live participation.
Zimmer Biomet (NYSE: ZBH) appointed Jonathan M. Vigdorchik, M.D., as Chief Science, Technology and Medical Affairs Officer, effective April 14, 2026. He will report to Ivan Tornos and oversee the company's global technology portfolio, including AI, robotics, smart implants and data, plus Medical Education and the Global Advisory Board.
Dr. Vigdorchik joins from Hospital for Special Surgery, previously served as Zimmer Biomet Chief Medical Technology Advisor for Adult Reconstruction and Hip Implants, and holds academic roles including Associate Professor at Weill Cornell.